RDX-002

RDX-002 is a first-in-class, potent, selective, and gut-specific small molecule inhibitor of intestinal microsomal triglyceride transfer protein (iMTP). By inhibiting iMTP, RDX-002 reduces the absorption of triglycerides and cholesterol after meals, leading to decreased delivery of these lipids—and therefore calories—to the body. This mechanism is intended to combat drug-induced weight gain and improve cardiometabolic risk factors. The drug has been studied in multiple Phase 1 and Phase 2 clinical trials involving approximately 500 healthy subjects and patients dosed for up to 84 days. In these studies, RDX-002 lowered post-prandial triglyceride levels, circulating low-density lipoprotein cholesterol (LDL-C), free fatty acids, HbA1c in diabetic patients, and reduced body weight without significant adverse effects beyond mild-to-moderate gastrointestinal symptoms. It is being developed primarily for managing antipsychotic-induced weight gain (AIWG) as well as preventing weight rebound following discontinuation of GLP-1 agonists used in obesity treatment[1][2][4][5][6][7].